ArticleProceedings of the National Academy of Sciences of the United States of America2007
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 66 citations in OpenAlex.
- Exploring microRNAs in craniofacial regenerative medicine.Biochemical Society transactions · 2023Review
- MicroRNAs in T Cell-Immunotherapy.International journal of molecular sciences · 2022Review
- MicroRNAs as therapeutic targets in breast cancer metastasis.Drug delivery and translational research · 2022Review
- Small Non-Coding RNAs in Leukemia.Cancers · 2022Review
- MicroRNAs Regulating Autophagy in Neurodegeneration.Advances in experimental medicine and biology · 2021Article
- BCR-ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in phCancer medicine · 2018Article
- Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.Human gene therapy methods · 2017Review
- Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy.Current genomics · 2015Article
- Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells.Oncotarget · 2015Article
- Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility.PloS one · 2015Article
- Inhibition of Dengue virus 2 replication by artificial micrornas targeting the conserved regions.Nucleic acid therapeutics · 2013Article
- Article
- Article
- MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics.Prostate cancer and prostatic diseases · 2012Review
- Article
- Approaches to manipulating microRNAs in neurogenesis.Frontiers in neuroscience · 2012Article
- miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans.The Journal of clinical investigation · 2011Article
- Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo.Blood cancer journal · 2011Article
- MicroRNAs in skin and wound healing.Physiological genomics · 2011Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many cancers and leukemias are associated with strong dominant oncogenic mutations that activate tyrosine kinases and other classes of molecules, including transcription factors and antiapoptotic mechanisms. Some of these events can be targeted with small molecules or antibody-based therapeutics, but many remain intractable. In addition, cancer-related enzyme targets can often mutate, and drug-resistant variants are selected. Therapies directed at the mRNA encoding dominant oncogenes could provide a more global set of technologies for cancer treatment. To test this concept, we have used the model of transformation of hematopoietic cells by the chimeric Bcr-Abl oncogene, a highly activated tyrosine kinase. Our results show that tandem arrays of miRNA mimics, but not single miRNA mimics, directed against the Abl portion of the mRNA and introduced by lentiviral vectors can effectively alter the leukemogenic potency when the degree of suppression of expression of Bcr-Abl is reduced >200-fold from control levels. Only methods capable of such dramatic sustained reduction in the level of expression of highly activated kinase oncogenes are likely to be effective in controlling malignant cell populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.